Clinical trials: ICC
Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant concurrent chemoradiotherapy with simultaneous integrated boost following hepatectomy for intrahepatic cholangiocarcinoma…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin, Lymph Node Involvement
- Trial name
- NCT07063888
- Testing
- Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Intrahepatic Cholangiocarcinoma (Icc)
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line…
- Trial name
- NCT06648525
- Testing
- Adebrelimab, Irinotecan liposomes, Lenvatinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Harbin Medical University
Peripheral ICC, PICC
A Comparative, Retrospective Chart Review of Intended Dwell Time of a PICC Line
This is a retrospective, matched pair comparative post market review of 4Fr Single Lumen PICC lines. The subjects will be matched by the timeframe of when the HydroPICCs were inserted.
- Trial name
- NCT04656548
- Testing
- HydroPICC
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Access Vascular Inc
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital
Intrahepatic Cholangiocarcinoma
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with advanced intrahepatic…
- Trial name
- NCT04454905
- Testing
- Camrelizumab, Apatinib
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
This is a Phase III, prospective, randomized, three-arm, double-blind, placebo-controlled, international multicenter study to evaluate the efficacy and safety of toripalimab in combination with lenvatinib and gemcitabine-based…
- Trial name
- NCT05342194
- Testing
- Toripalimab, Lenvatinib mesylate capsules, Oxaliplatin for injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Intrahepatic Cholangiocarcinoma (Icc), HAIC
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
At present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab
- Trial name
- HAIC-quad (NCT06859684)
- Testing
- Durvalumab, hepatic arterial infusion chemotherapy (HAIC), Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
This is single-arm, observational, academic, investigator-driven study investigating the efficacy of liver transplantation after successful and sustained downstaging/tumor control of liver-limited unresectable intrahepatic…
- Trial name
- iCOLA (NCT06862934)
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Cancer
PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer
Immunotherapy is probably, since the development of therapies targeting EGFR mutations or ALK rearrangement, the most attractive therapeutic perspective in the management of metastatic lung cancer.
- Trial name
- IMMUNO-PREDICT (NCT02827344)
- Testing
- blood sample collection for CTC and MDSC analysis
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocarcinoma (ICC) that may be technically resectable but is difficult to remove directly by surgery.
- Trial name
- H-FROG (NCT07847710)
- Testing
- Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin
- Where
- China
- Volunteers
- 81 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Intrahepatic Cholangiocarcinoma (Icc)
Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study
Second-line regimen with or without consolidative radiotherapy in patients with oligometastatic/locally advanced unresectable intrahepatic cholangiocarcinoma: an open-label, randomised, controlled study.
- Trial name
- SED-RO-ICC (NCT06946849)
- Testing
- radiotherapy, FOLFIRI or FOLFOX or Regorafenib
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.
- Trial name
- NCT04782804
- Testing
- Capecitabine, PD-1 Antibody（Tislelizumab）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma
Next Generation Sequencing in Intrahepatic Cholangiocarcinoma
The aim of the present study is to perform a comprehensive molecular characterization of intrahepatic cholangiocarcinoma (ICC) in patients exposed to well-known or putative risk factors (such as asbestos) for this malignancy, in…
- Trial name
- EtherBil (NCT02184871)
- Testing
- exposure to different risk factors and molecular assessment
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Bologna
Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Among resectable biliary tract cancers (BTC) patients, surgery has historically been the standard treatment, but even with curative surgery, the cure rates remain relatively low, with most patients relapsing in the short term and…
- Trial name
- NCT06739252
- Testing
- Gemcitabine Oxaliplatin and 5FU
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Intrahepatic Cholangiocarcinoma (Icc), Liver Injury
Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed.
- Trial name
- NCT07760038
- Testing
- Phycocyanin, Maltodextrin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Intrahepatic Cholangiocarcinoma (Icc)
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line…
- Trial name
- CASTLE-ZS-02 (NCT07070700)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib, cryoablation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma (Icc)
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
This study aims to evaluate whether adding celecoxib to standard therapy can improve clinical outcomes in patients with advanced intrahepatic cholangiocarcinoma.
- Trial name
- NCT07632235
- Testing
- Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin, Pembrolizumab + Gemcitabine/Cisplatin
- Where
- 5 sites in China
- Volunteers
- 112 people
- Sponsor
- Shanghai 6th People's Hospital
Subarachnoid Hemorrhage (SAH)
ICP Versus Intracranial Compliance Guided Management in SAH
The purpose of this study is to determine whether treatment guided also by ICP mean wave amplitude improves outcome compared to international standard care in patients with SAH.
- Trial name
- NCT00248690
- Testing
- ICP mean wave amplitude
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Oslo University Hospital
Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement.
- Trial name
- NCT04353375
- Testing
- HMPL-453
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Hutchmed